Insmed to Present at CBI Follow-On Biologics Conference
22 Avril 2008 - 3:00PM
PR Newswire (US)
RICHMOND, Va., April 22 /PRNewswire-FirstCall/ -- Insmed Inc.
(NASDAQ:INSM), a developer of follow-on biologics (FOBs) and
biopharmaceuticals, announced today that Geoffrey Allan, Ph.D., CEO
of Insmed, will present at the Center for Business Intelligence
(CBI) conference on FOBs, on April 29, 2008 at 2:15 PM Eastern Time
in Arlington, Virginia. The conference, entitled "Evaluate the
Legislative, Economic and Scientific Implications of the Industry
Debate on: Biosimilars and Follow-On Biologics," will be held at
the Doubletree Hotel Crystal City in Arlington, Virginia, and will
run from Monday, April 28 through Tuesday, April 29. The conference
will bring together corporate, regulatory, financial, and legal
experts in the field of FOBs. Dr. Allan will discuss Insmed's
comprehensive portfolio of FOBs, and the Company's initiatives
aimed at helping garner awareness of the need to establish a
regulatory pathway for FOBs in the U.S. so that patients can be
provided greater choice through access to these important
medicines. His presentation will be entitled, "The Promise of
Follow-On Biologics: The Need to Match Policy with Capability and
Demand." Dr. Allan's presentation will be available on Insmed's
website at http://www.insmed.com/ following the conference. The
Follow-on Biologics Market According to published reports, an
estimated $10 billion worth of biologic drugs are expected to come
off patent by 2010, with an additional $10 billion by 2015. FOBs
would provide safe and effective therapies at a reduced cost
following the expiration of the original product's patent. A recent
econometric study commissioned by Insmed and conducted by economist
Dr. Robert J. Shapiro, former Under Secretary of Commerce in the
Clinton Administration, found that "...generic versions of the top
12 categories of biologic treatments with patent protections that
have expired or that are due to expire in the near future could
save Americans $67 billion to $108 billion over 10 years and $236
billion to $378 billion over 20 years." About Insmed Insmed Inc. is
a biopharmaceutical company with unique protein process development
and manufacturing experience and a proprietary protein platform
aimed at niche markets with unmet medical needs. For more
information, please visit http://www.insmed.com/. Forward-Looking
Statements This release contains forward-looking statements which
are made pursuant to provisions of Section 21E of the Securities
Exchange Act of 1934. Investors are cautioned that such statements
in this release, including statements relating to planned clinical
study design, regulatory and business strategies, plans and
objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, we may lack
financial resources to complete development of product candidates,
the FDA may interpret the results of studies differently than us,
competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical
industry may experience negative market trends, our entrance into
the follow on biologics market may be unsuccessful, our common
stock could be delisted from the Nasdaq Capital Market and other
risks and challenges detailed in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2007. Readers are
cautioned not to place undue reliance on any forward-looking
statements which speak only as of the date of this release. We
undertake no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events.
DATASOURCE: Insmed Inc. CONTACT: Investors, Brian Ritchie of FD,
+1-212-850-5683, ; or Corporate Communications, John Procter of
Gibraltar Associates, +1-202-879-5808, , both for Insmed Inc. Web
site: http://www.insmed.com/
Copyright
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024